NASDAQ:CORT - Corcept Therapeutics Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$12.47 +0.20 (+1.63 %)
(As of 08/14/2018 04:00 PM ET)
Previous Close$12.27
Today's Range$12.00 - $12.59
52-Week Range$11.55 - $25.96
Volume2.38 million shs
Average Volume1.57 million shs
Market Capitalization$1.54 billion
P/E Ratio28.34
Dividend YieldN/A
Beta1.7
Corcept Therapeutics logoCorcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270

Debt

Debt-to-Equity RatioN/A
Current Ratio6.39
Quick Ratio6.23

Price-To-Earnings

Trailing P/E Ratio28.34
Forward P/E Ratio17.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$159.20 million
Price / Sales9.09
Cash Flow$0.4330 per share
Price / Cash28.80
Book Value$1.67 per share
Price / Book7.47

Profitability

EPS (Most Recent Fiscal Year)$0.44
Net Income$129.12 million
Net Margins68.32%
Return on Equity38.53%
Return on Assets33.42%

Miscellaneous

Employees136
Outstanding Shares116,050,000
Market Cap$1.54 billion

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) issued its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.24 by $0.04. The biotechnology company had revenue of $62.31 million for the quarter, compared to analyst estimates of $68.49 million. Corcept Therapeutics had a return on equity of 38.53% and a net margin of 68.32%. The firm's quarterly revenue was up 75.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.13 EPS. View Corcept Therapeutics' Earnings History.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Corcept Therapeutics.

What price target have analysts set for CORT?

4 Wall Street analysts have issued 1 year target prices for Corcept Therapeutics' shares. Their predictions range from $11.00 to $32.00. On average, they expect Corcept Therapeutics' stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 90.5% from the stock's current price. View Analyst Price Targets for Corcept Therapeutics.

What is the consensus analysts' recommendation for Corcept Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corcept Therapeutics.

Are investors shorting Corcept Therapeutics?

Corcept Therapeutics saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 18,122,510 shares, an increase of 8.0% from the July 13th total of 16,779,082 shares. Based on an average daily volume of 1,226,071 shares, the days-to-cover ratio is currently 14.8 days. Currently, 17.7% of the shares of the company are sold short. View Corcept Therapeutics' Current Options Chain.

Who are some of Corcept Therapeutics' key competitors?

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the folowing people:
  • Dr. Joseph K. Belanoff, Co-Founder, CEO, Pres & Director (Age 61)
  • Mr. Gary Charles Robb, CFO, Chief Accounting Officer & Sec. (Age 55)
  • Mr. Sean Maduck, Sr. VP of Commercial (Age 41)
  • Dr. Robert S. Fishman, Chief Medical Officer (Age 56)
  • Dr. Hazel Hunt Ph.D., Sr. VP of Research

Has Corcept Therapeutics been receiving favorable news coverage?

News headlines about CORT stock have trended somewhat positive on Tuesday, according to Accern. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corcept Therapeutics earned a media and rumor sentiment score of 0.17 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 48.17 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Corcept Therapeutics.

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.32%), Federated Investors Inc. PA (10.34%), Ingalls & Snyder LLC (6.35%), Renaissance Technologies LLC (3.77%), Acadian Asset Management LLC (2.42%) and Dimensional Fund Advisors LP (1.44%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright, Renee D Gala and Robert S Fishman. View Institutional Ownership Trends for Corcept Therapeutics.

Which institutional investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Acadian Asset Management LLC, Renaissance Technologies LLC, Russell Investments Group Ltd., American Century Companies Inc., Globeflex Capital L P, GSA Capital Partners LLP and Smith Asset Management Group LP. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr and Robert S Fishman. View Insider Buying and Selling for Corcept Therapeutics.

Which institutional investors are buying Corcept Therapeutics stock?

CORT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Ingalls & Snyder LLC, Fuller & Thaler Asset Management Inc., KBC Group NV, AJ Wealth Strategies LLC, HL Financial Services LLC, Wells Fargo & Company MN and Oak Ridge Investments LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $12.47.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $1.54 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]


MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  569
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/14/2018 by MarketBeat.com Staff

Featured Article: Dividend

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.